









Markets
/
Stocks
/
nasdaq-artl
/

Artelo Biosciences Inc

ARTL

1.470USD

+0.100+7.30%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.29MMarket Cap

LossP/E TTM



Artelo Biosciences Inc

1.470

+0.100+7.30%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Artelo Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Artelo Biosciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 163 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Artelo Biosciences Inc's Score

Industry at a Glance

Industry Ranking

163 / 392

Overall Ranking

312 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Artelo Biosciences Inc Highlights

StrengthsRisks

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Overvalued

The company’s latest PE is -0.08, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 14.03K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.50.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

30.000

Target Price

+471.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Artelo Biosciences Inc is 6.52, ranking 246 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

7.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Artelo Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Artelo Biosciences Inc is 8.69, ranking 26 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -50.20% below the recent high of -0.04 and -1896.56% above the recent low of -1.51.

Score

Industry at a Glance

Previous score

8.69

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 163/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Artelo Biosciences Inc is 6.00, ranking 340 out of 392 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 30.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

30.000

Target Price

+471.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Artelo Biosciences Inc

ARTL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Artelo Biosciences Inc is 6.81, ranking 164 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.78 and the support level at 1.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

0.34

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Sell

RSI(14)

42.176

Neutral

STOCH(KDJ)(9,3,3)

16.249

Oversold

ATR(14)

0.145

High Vlolatility

CCI(14)

-136.699

Sell

Williams %R

77.320

Sell

TRIX(12,20)

0.110

Sell

StochRSI(14)

54.695

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.490

Sell

MA10

1.626

Sell

MA20

1.620

Sell

MA50

1.637

Sell

MA100

2.653

Sell

MA200

5.782

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Artelo Biosciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 1.41%, representing a quarter-over-quarter decrease of 34.62%. The largest institutional shareholder is The Vanguard, holding a total of 14.03K shares, representing 0.69% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

126.00

+41.57%

DRW Securities, LLC

17.18K

The Vanguard Group, Inc.

Star Investors

14.03K

+204.16%

Farb (Daniel Stuart)

5.10K

-96.67%

Gorgas (Gregory D)

3.41K

Morgan Stanley & Co. LLC

1.10K

Matsui (Connie L)

630.00

Citi Investment Research (US)

477.00

+5200.00%

Blayney (Douglas W)

139.00

Kelly (Steven)

139.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Artelo Biosciences Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.